An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
Latest Information Update: 18 May 2020
At a glance
- Drugs ADVM-022 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms OPTIC
- Sponsors Adverum Biotechnologies
- 13 May 2020 Planned End Date changed from 1 Feb 2022 to 1 Jun 2022.
- 13 May 2020 Planned primary completion date changed from 1 Feb 2022 to 1 Jun 2022.
- 04 May 2020 According to an Adverum Biotechnologies media release, Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates is a principal investigator in the OPTIC trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History